Drug intelligence / Profile preview

GBE761

Development stage: Unknown
Lead developer: Schwabe
Modality: Small Molecules
Administration: Oral

Overview

GBE761 is a standardized extract of *Ginkgo biloba* being developed by the University of Brasilia as an otoprotective agent. It is primarily indicated for the prevention of cisplatin-induced ototoxicity and hearing loss in patients undergoing chemotherapy. The extract's mechanism of action is centered on its potent antioxidant properties and its ability to scavenge reactive oxygen species (ROS), thereby protecting the outer hair cells of the cochlea from oxidative damage. Clinical research, including a Phase 2 study, has utilized distortion product otoacoustic emission (DPOAE) testing to evaluate its efficacy, showing that GBE761 can be administered at a dose of 240 mg/day without interfering with the antitumor activity of cisplatin.

Other names: Ginkgo biloba extract

Beyond the preview

Go deeper on GBE761.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBE761.

Explore the full profile